FDA Approves the Use of Luzu Cream in Younger Patients

Luzu is indicated for the topical treatment of interdigital tinea pedis, tinea cruris and tinea corporis
Luzu is indicated for the topical treatment of interdigital tinea pedis, tinea cruris and tinea corporis

The Food and Drug Administration (FDA) has approved the use of Luzu Cream, 1% (luliconazole; Ortho Dermatologics) for the treatment of pediatric patients ≥12 years of age. Previously, the treatment had only been approved for those ≥18 years old.

Luzu, an azole antifungal, is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum.

Related Articles

The FDA approval to expand the indication was based on two postmarketing requirement studies conducted in pediatric patients. “Though anyone at any age can get infected with athlete's foot, jock itch and ringworm, because they are very contagious, treatment options are limited for children,” said Bill Humphries, executive vice president of Dermatology, Ortho Dermatologics. “We are pleased that the FDA recognized the benefits of treatment with Luzu for pediatric patients."

Luzu Cream, 1% is supplied in 60g tubes; each gram contains 10mg of luliconazole.

For more information visit Ortho-Dermatologics.com.